IBB ETF Outperforms S&P 500 on Biotech Rally

**Implied Volatility / Movement:** IBB returned 26% over three months ending September 4, 2026, while SPY returned 4%. Over one year, IBB is up 51%. The SPDR S&P Biotech ETF (XBI), an equal-weight alternative, returned 34% year-to-date. The iShares Biotechnology ETF (IBB) has surpassed the S&P 500 (SPY) by 22 percentage points over the past quarter, fueled by a resurgence in biotech acquisitions. This rally signifies a shift for a sector that had previously underperformed the broader market.

Large pharmaceutical companies are actively acquiring mid- and small-cap biotech firms to secure late-stage drug candidates. This strategy aims to mitigate the revenue impact of major branded drugs losing patent exclusivity in the coming years. IBB's portfolio, weighted by market capitalization, is heavily influenced by its top holdings: Vertex Pharmaceuticals (VRTX) at approximately 8%, Amgen (AMGN) near 8%, Gilead (GILD) at around 7%, and Regeneron (REGN) at nearly 5%. These four companies collectively contribute substantially to the ETF's overall returns.

For comparison, the SPDR S&P Biotech ETF (XBI), which employs an equal-weight methodology, has shown stronger year-to-date performance of 34% compared to IBB's 26%, indicating a greater exposure to clinical-stage volatility. IBB, with an expense ratio of 0.44%, held approximately $9.1 billion in net assets as of June 30, 2026. Investors are advised to view IBB as a satellite holding, potentially ranging from 3% to 7% of a portfolio, given its significant recent gains.